To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

This study tests a new immunotherapy drug called carbognilumab combined with standard chemotherapy as a first-line treatment for patients with advanced lung cancer that has a specific genetic mutation (KEAP1/STK11) and cannot be treated with targeted therapies. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced or recurrent non-small cell lung cancer - Your tumor has a STK11 mutation, confirmed by genetic testing - Your tumor does not have other mutations that have targeted treatments (e.g., EGFR, ALK, ROS1) - You have not yet received systemic treatment for advanced disease - Your organ function is adequate **You may NOT be eligible if...** - You have another targetable mutation with available treatment options - You have active autoimmune disease or are on immunosuppressive medications - You have uncontrolled brain metastases - You have serious heart, lung, or liver disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.